Personalis, Inc. (PSNL) stock
PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30345% above fair value
$14.98+0.18 (+1.22%)
Close on Nov 18, 2026Market cap $1.60BP/E –Yield –
Personalis revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Personalis's revenue for the twelve months ending Jun 30, 2026 was $69.67M, down 13.3% year over year. For fiscal 2025 it was $69.65M, down 17.7% from the year before. The highest annual figure on record is $85.49M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.65M | -17.7% |
| FY2024 | Dec 31, 2024 | $84.61M | +15.2% |
| FY2023 | Dec 31, 2023 | $73.48M | +13.0% |
| FY2022 | Dec 31, 2022 | $65.05M | -23.9% |
| FY2021 | Dec 31, 2021 | $85.49M | +8.7% |
| FY2020 | Dec 31, 2020 | $78.65M | +20.6% |
| FY2019 | Dec 31, 2019 | $65.21M | +72.6% |
| FY2018 | Dec 31, 2018 | $37.77M | +302.2% |
| FY2017 | Dec 31, 2017 | $9.39M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.36M | +30.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.47M | -24.9% |
| Q4 FY2025 | Dec 31, 2025 | $17.35M | +3.2% |
| Q3 FY2025 | Sep 30, 2025 | $14.50M | -43.6% |
| Q2 FY2025 | Jun 30, 2025 | $17.20M | -23.8% |
| Q1 FY2025 | Mar 31, 2025 | $20.61M | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | $16.80M | -14.6% |
| Q3 FY2024 | Sep 30, 2024 | $25.71M | +40.9% |
| Q2 FY2024 | Jun 30, 2024 | $22.58M | +35.2% |
| Q1 FY2024 | Mar 31, 2024 | $19.53M | +3.5% |
| Q4 FY2023 | Dec 31, 2023 | $19.68M | +17.7% |
| Q3 FY2023 | Sep 30, 2023 | $18.25M | +22.8% |
| Q2 FY2023 | Jun 30, 2023 | $16.70M | -8.4% |
| Q1 FY2023 | Mar 31, 2023 | $18.86M | +23.9% |
| Q4 FY2022 | Dec 31, 2022 | $16.72M | -19.1% |
| Q3 FY2022 | Sep 30, 2022 | $14.86M | -33.3% |
| Q2 FY2022 | Jun 30, 2022 | $18.24M | -15.8% |
| Q1 FY2022 | Mar 31, 2022 | $15.23M | -27.1% |
| Q4 FY2021 | Dec 31, 2021 | $20.68M | +2.5% |
| Q3 FY2021 | Sep 30, 2021 | $22.26M | +12.3% |
| Q2 FY2021 | Jun 30, 2021 | $21.67M | +11.2% |
| Q1 FY2021 | Mar 31, 2021 | $20.88M | +9.0% |
| Q4 FY2020 | Dec 31, 2020 | $20.18M | +11.1% |
| Q3 FY2020 | Sep 30, 2020 | $19.82M | +15.5% |
| Q2 FY2020 | Jun 30, 2020 | $19.50M | +23.2% |
| Q1 FY2020 | Mar 31, 2020 | $19.16M | +36.1% |
| Q4 FY2019 | Dec 31, 2019 | $18.15M | +38.0% |
| Q3 FY2019 | Sep 30, 2019 | $17.15M | +47.2% |
| Q2 FY2019 | Jun 30, 2019 | $15.83M | +79.8% |
| Q1 FY2019 | Mar 31, 2019 | $14.08M | +238.0% |
| Q4 FY2018 | Dec 31, 2018 | $13.16M | – |
| Q3 FY2018 | Sep 30, 2018 | $11.65M | – |
| Q2 FY2018 | Jun 30, 2018 | $8.80M | – |
| Q1 FY2018 | Mar 31, 2018 | $4.16M | – |
See a number that looks wrong?